Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Eberhardt, W.
Right arrow Articles by Stamatis, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eberhardt, W.
Right arrow Articles by Stamatis, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:365-367, 2004
© 2004 European Society for Medical Oncology

Preoperative chemoradiation approaches to locally advanced non-small-cell lung cancer: one man’s pride, another man’s burden?

W. Eberhardt1, M. Stuschke2 and G. Stamatis3

Departments of 1 Internal Medicine and 2 Radiation Oncology, West German Cancer Centre Essen, University of Duisburg, Essen; 3 Department of Thoracic Endoscopy and Surgery, Ruhrlandklinik, Germany E-mail: wilfried.eberhardt@uni-essen.de

The first 150 words of the full text of this article appear below.

Defining the problem

Has there been any major progress in the combined modality treatment for stage III locally advanced non-small-cell lung cancer (NSCLC) within the last 10 years? The answer is certainly yes, but currently we have to admit that the absolute gain for our patients has been relatively small, when looking from the broader perspective of the general patient population with NSCLC [1]. Differences in 5-year survival rates that have been achieved by complex bi- or tri-modality protocols have generally been observed in the range of between 3% and 7% improvement [2, 3]. Some therapists may be satisfied with these figures, others may not.

This naturally contrasts with the situation in a given individual patient case, in whom optimised approaches have led to definite cure of the disease, whereas years before only palliation could be achieved by local treatment modalities alone [2, 4]. Therefore, . . . [Full Text of this Article]

Preoperative concurrent chemoradiotherapy: the paths to tri-modality

Interpreting the results of this feasibility trial

What else can we learn from trials that have been reported within the last 10 years?

One man’s pride, another man’s burden

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 RadiologyHome page
R. F. Munden, S. S. Swisher, C. W. Stevens, and D. J. Stewart
Imaging of the Patient with Non-Small Cell Lung Cancer
Radiology, December 1, 2005; 237(3): 803 - 818.
[Abstract] [Full Text] [PDF]